AAS
FLNA

Ameritas Advisory Services’s Filana Therapeutics FLNA Stock Holding History

Ameritas Advisory Services’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30
Closed -$724 – 2163
2023
Q1 		$724 Buy
+30
New +$831 ﹤0.01% 2598

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameritas Advisory Services's FLNA Position: Q2 2023 in Review

Ameritas Advisory Services sold out of Filana Therapeutics (FLNA) in Q2 2023, closing a stake of 30 shares — an estimated $724 sold.

Ameritas Advisory Services first reported a position in FLNA in Q1 2023 and held it in 1 quarter. The position peaked at $724 in Q1 2023. 152 funds tracked by Wall St. Rank hold FLNA as of Q2 2023.

  • Ameritas Advisory Services reported no remaining Filana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ameritas Advisory Services sold 30 Filana Therapeutics shares in Q2 2023, an estimated $724.
  • Ameritas Advisory Services first reported a position in Filana Therapeutics in Q1 2023 and held it in 1 quarter.
  • Ameritas Advisory Services's Filana Therapeutics position peaked at $724 in Q1 2023.
  • 152 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2023.

Based on Ameritas Advisory Services's 13F filing for Q2 2023, filed 25 Jul 2023.